Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination. Continue your routine care with us by scheduling an in-person appointment or Video Visit.

Gabapentin adjunctive therapy in neuropathic pain states.

TitleGabapentin adjunctive therapy in neuropathic pain states.
Publication TypeJournal Article
Year of Publication1996
AuthorsRosner H, Rubin L, Kestenbaum A
JournalClin J Pain
Volume12
Issue1
Pagination56-8
Date Published1996 Mar
ISSN0749-8047
KeywordsAcetates, Adult, Aged, Amines, Analgesics, Cyclohexanecarboxylic Acids, Facial Pain, Female, gamma-Aminobutyric Acid, Herpesviridae Infections, HIV Infections, Humans, Intervertebral Disc Displacement, Male, Middle Aged, Neuralgia, Pain, Intractable, Peripheral Nervous System Diseases
Abstract

OBJECTIVE: This is a report of a trial of the new antiepileptic agent gabapentin in patients with intractable neuropathic pain.

DESIGN: A case series of patients with a diagnosis of neuropathic pain whose previous management was inadequate were given oral gabapentin in increasing doses and were followed for a minimum of 2 months, monitored for efficacy and side effects.

SETTING: An outpatient pain management center located within a major university medical center.

PATIENTS: Convenience sample of patients referred for management of intractable neuropathic pain.

INTERVENTIONS: Simplification of existing pharmacologic management, addition of gabapentin, and attempted reduction of opiate analgesic doses.

MAIN OUTCOME MEASURES: Patient self-reports and pain scores in successive office visits.

RESULTS: Gabapentin provides analgesic activity for patients with neuropathic pain and has the advantage of a low side effect profile and drug toxicity.

Alternate JournalClin J Pain
PubMed ID8722736